RWS

Hyundai Mobis to present the latest automotive innovations in Europe

Retrieved on: 
Thursday, June 9, 2022

Orders from Europe have doubled every year for the last three years, Mobis to diversify its order portfolio with AR HUDs, Grille Lighting, and RWS.

Key Points: 
  • Orders from Europe have doubled every year for the last three years, Mobis to diversify its order portfolio with AR HUDs, Grille Lighting, and RWS.
  • Hyundai Mobis will hold a Tech Show for two days on June 14 and 15 to present its latest innovations to its customers.
  • According to Axel Maschka, Head of Global OE Sales, Executive Vice President at Hyundai Mobis, "Hyundai Mobis will increase the number of new orders for our latest products to satisfy the needs of European Customers and mount diverse Tech Marketing campaigns."
  • Hyundai Mobis operates R&D headquarter in Korea, with 4 technology centers in Germany, China, India and the United States.

Hyundai Mobis to Hold Tech Show in France with Breakthrough Automotive Technologies

Retrieved on: 
Thursday, June 9, 2022

SEOUL, South Korea and PARIS, June 9, 2022 /PRNewswire/ -- Hyundai Mobis (KRX: 012330) is quickly developing its presence in the European Market, with ingenious technologies for autonomous driving, infotainment, and electrification.

Key Points: 
  • SEOUL, South Korea and PARIS, June 9, 2022 /PRNewswire/ -- Hyundai Mobis (KRX: 012330) is quickly developing its presence in the European Market, with ingenious technologies for autonomous driving, infotainment, and electrification.
  • Hyundai Mobis will hold a Tech Show for two days on June 14 and 15 to present its latest innovations to its customers.
  • Hyundai Mobis is the global no.7 global automotive supplier, headquartered in Seoul, Korea.
  • Hyundai Mobis operates R&D headquarter in Korea, with 4 technology centers in Germany, China, India and the United States.

RWS Announces Appointment of General Managers to Language and Content Technology Division

Retrieved on: 
Wednesday, June 8, 2022

RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property services, today announces the appointment of four General Managers to lead its language and content technology product lines, holding responsibility for revenue and profit, operations, research and development, alongside delivery.

Key Points: 
  • RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property services, today announces the appointment of four General Managers to lead its language and content technology product lines, holding responsibility for revenue and profit, operations, research and development, alongside delivery.
  • The General Managers will report into Thomas Labarthe, President of Language and Content Technology, who will continue to oversee the division.
  • These appointments within our Language and Content Technology division will ensure that we will be able to continue delivering an outstanding service and continually innovate our technology products in order to support our clients with their language and content challenges.
  • Mihai Vlad, as General Manager of Language Weaver, will drive the development of RWSs Machine Translation and Linguistic AI technologies.

IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

Retrieved on: 
Tuesday, June 7, 2022

IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the companys Real World Solutions (RWS) business, effective July 7, 2022.

Key Points: 
  • IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the companys Real World Solutions (RWS) business, effective July 7, 2022.
  • Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA.
  • Dr. Mack also serves on the advisory board of the Carolina Health Informatics Program, the ISPE Real World Evidence task force, and co-chairs the Medical Device Epidemiology Network Scientific Oversight Committee.
  • IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.

Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Retrieved on: 
Friday, June 3, 2022

BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time.

Key Points: 
  • BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time.
  • Investors and the general public are invited to listen to the Goldman Sachs fireside chat, which will be accessible on the Events page under the Investors & Media section of theMyovantwebsite at www.myovant.com .
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.
  • Founded in 2016,Myovanthas executed five successful Phase 3 clinical trials across oncology and womens health leading to two regulatory approvals by theU.S.

Amanda Newton appointed to lead RWS’s Strategic Solutions Group

Retrieved on: 
Wednesday, June 1, 2022

RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property services, today announces that Amanda Newton will lead the companys recently formed Strategic Solutions Group (SSG) as Executive Vice President.

Key Points: 
  • RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property services, today announces that Amanda Newton will lead the companys recently formed Strategic Solutions Group (SSG) as Executive Vice President.
  • Amanda will hold responsibility for the SSGs growth, client relationships and delivery, and for developing propositions and new solutions that enable clients to reach their customers in any language, or device they choose.
  • The SSG, part of RWSs Language Services division, works closely with major accounts, and clients of all sizes who are going global with specialized localization services.
  • Going global is easier said than done, explains Amanda Newton, EVP of RWSs Strategic Solutions Group.

Emer Dolan joins RWS’s Executive Team as President of Enterprise Internationalization Group

Retrieved on: 
Thursday, May 26, 2022

RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property services, today announces the appointment of Emer Dolan to President of RWSs Enterprise Internationalization Group (EIG) and as a member of the RWS Executive Team.

Key Points: 
  • RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property services, today announces the appointment of Emer Dolan to President of RWSs Enterprise Internationalization Group (EIG) and as a member of the RWS Executive Team.
  • Emer will oversee the EIGs commercial operations and the delivery of highly integrated and effective solutions for RWSs enterprise clients.
  • Theyre open to new ideas, innovations and strategies that will enable them to stay ahead in their field, explains Emer Dolan, President of RWSs Enterprise Internationalization Group.
  • Emer has 25 years experience in internationalization and enterprise software services.

RWS Names Maria Schnell as Chief Language Officer

Retrieved on: 
Thursday, May 12, 2022

RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property services, today announces the appointment of Maria Schnell as Chief Language Officer.

Key Points: 
  • RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property services, today announces the appointment of Maria Schnell as Chief Language Officer.
  • As a member of the Executive Team Maria Schnell will lead RWSs recently launched Language eXperience Delivery (LXD) platform.
  • Being a truly global organization brings distinct benefits, explains Maria Schnell, Chief Language Officer at RWS.
  • RWS Holdings plc is a unique, world-leading provider of technology-enabled language, content and intellectual property services.

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.

Key Points: 
  • (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.
  • Additionally, we plan to begin dosing patients in REACH, our Phase 3 trial of losmapimod in FSHD, in the second quarter.
  • Open next dose cohort in Phase 1b trial in people with sickle cell disease in the second quarter of 2022.
  • ET to discuss the Companys first quarter 2022 recent business highlights and financial results.

Global Language Service Markets, 2021-2022 & 2025: Focus on Translation and Transcreation, Interpreting, Localization Services

Retrieved on: 
Thursday, April 7, 2022

The report provides analysis of the global language service market, with detailed analysis of market size and growth, and segmentation of the industry.

Key Points: 
  • The report provides analysis of the global language service market, with detailed analysis of market size and growth, and segmentation of the industry.
  • There are many segments which fall under language service industry such as translations, editing for authors, language interpretation, language education, computer assisted translations, terminology extractions, language localization, software localization and machine translations.
  • The global language service market is expected to increase at high growth rates during the coming years.
  • The global language service market is supported by various growth drivers, such as increasing globalization, growing e-commerce, increasing online and offline content volume, etc.